Baloxavir marboxil is an antiviral drug for the treatment of influenza A and influenza B infections. It works as a cap-endonuclease inhibitor with a unique mechanism of action when compared to the currently existing neuraminidase inhibitor drugs.
Baroxavir dipivoxil is suitable for patients ≥ 12 years old who suffer from acute uncomplicated influenza and whose symptoms do not exceed 48 hours. Attention should be paid to the limitations of medication: influenza virus changes over time, and there are factors such as virus type and subtype. Once the drug resistance of the virus and the pathogenicity of the virus change, the clinical efficacy of antiviral drugs may be weakened. When deciding whether to take basalovir dipivoxil, the available information on the sensitivity of the local epidemic virus strain to the drug should be considered.
